share_log

贝达药业(300558.SZ):目前BPI-16350项目二线适应症药品注册审评审批工作正在推进中

Betta Pharmaceutical (300558.SZ): Currently, the BPI-16350 project second-line indicated drug registration review and approval process is in progress

Gelonghui Finance ·  May 10 03:10

Gelonghui, May 10 | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that submitting a drug registration application with second-tier indications is a routine plan for the marketing of new drugs. Currently, the BPI-16350 project second-line drug registration review and approval process is in progress. If there are plans to expand indications in the future, the company will promptly announce and disclose them.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment